ZAXINE® (rifaximine) is now covered with special authorization on all provincial formularies, the NIHB and the Yukon Drug Programs Formulary in Canada!

Lupin Pharma Canada is pleased to announce that ZAXINE® is now listed across all Canadian provinces with the recent addition of PEI coverage.

The coverage criteria for PEI (special authority criteria) as of July 23, 2018 are:

For reducing the risk of overt hepatic encephalopathy (HE) recurrence (i.e., ≥2 episodes) in patients who meet the following criteria:

  • Patients are unable to achieve adequate control of HE recurrence with maximal tolerated dose of lactulose alone.

  • Must be used in combination with maximal tolerated doses of lactulose.

  • For patients not maintained on lactulose, information is required regarding the nature of the patient’s intolerance to lactulose.

For more information, click here.